2-bromo-5-methylpyridin-3-amine

We are 2-bromo-5-methylpyridin-3-amine CAS:34552-14-2 manufacturer and supplier in China, Pls send inquiry of to info@nbinno.com of visit www.nbinno.com our official website should you have any interests

Related News: With the improvement of people’s living standards and the aging degree, the demand for medicines has been increasing for a long time. Therefore, the transfer from finished medicines to bulk medicines has greatly promoted the demand for bulk medicines.CIS-5,8,11,14,17-EICOSAPENTAENOIC ACID METHYL ESTER CAS:2734-47-6 According to statistics, in the ten years from 2008 to 2017, a total of 13 “China Class 1” small-molecule chemical drugs were independently researched and developed by domestic enterprises in China and approved by the CFDA; in 2018, there were 10 varieties of domestic Class 1 new drugs. Approved for listing in China.2-Fluoro-3-Methoxyphenylboronic Acid According to statistics, in the ten years from 2008 to 2017, a total of 13 “China Class 1” small-molecule chemical drugs were independently researched and developed by domestic enterprises in China and approved by the CFDA; in 2018, there were 10 varieties of domestic Class 1 new drugs. Approved for listing in China.Tetrasulfuro de bis [3- (trietoxisilil) propil] CAS:40372-72-3 Mankind Pharmaceuticals on Monday said it has inked a licensing pact with Glenmark Pharmaceuticals to co-market diabetes drug Remogliflozin Etabonate in the country.In 2004, the National Development and Reform Commission, the former Ministry of Health, and the Ministry of Finance jointly formulated and promulgated the Administrative Measures for the Configuration and Use of Large Medical Equipment. This method uses X-ray electronic computer tomography (CT) devices and medical magnetic resonance imaging equipment, digital subtraction angiography X-ray machines of 800 mA or more as the management products of large-scale medical equipment, Purchase and use need to be reported to the provincial health administrative department for approval before approval. However, in recent years, with the comprehensive coverage of medical insurance, such basic medical facilities are being widely popularized, and the relevant implementation rules have directly linked the number of equipment to the number of doctors. Therefore, as the demand for imaging equipment continues to increase, it will have a greater boosting effect on the upstream contrast agent and its raw material market.